Fabienne Hartmann-Fritsch1, Daniela Marino1, Ernst Reichmann1. 1. Tissue Biology Research Unit, Department of Surgery, University Children's Hospital Zurich, Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Abstract
BACKGROUND: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard. METHODS: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application. RESULTS AND CONCLUSION: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.
BACKGROUND: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard. METHODS: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application. RESULTS AND CONCLUSION: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.
Authors: C Voltz-Girolt; P Celis; M Boucaumont; L D'Apote; M-H Pinheiro; M Papaluca-Amati Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2011-07 Impact factor: 1.513
Authors: Sophie Böttcher-Haberzeth; Thomas Biedermann; Clemens Schiestl; Fabienne Hartmann-Fritsch; Jörg Schneider; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2012-02 Impact factor: 1.827
Authors: C Schiestl; K Neuhaus; T Biedermann; S Böttcher-Haberzeth; E Reichmann; M Meuli Journal: Eur J Pediatr Surg Date: 2010-12-14 Impact factor: 2.191
Authors: Clemens Schiestl; Thomas Biedermann; Erik Braziulis; Fabienne Hartmann-Fritsch; Sophie Böttcher-Haberzeth; Margarete Arras; Nikola Cesarovic; Flora Nicolls; Carsten Linti; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2011-03 Impact factor: 1.827
Authors: Theodore T Nyame; H Abraham Chiang; Tripp Leavitt; Manuel Ozambela; Dennis P Orgill Journal: Plast Reconstr Surg Date: 2015-12 Impact factor: 4.730
Authors: Melanie Lindenberg; Valesca Retèl; Maartje Rohaan; Joost van den Berg; John Haanen; Wim van Harten Journal: BMC Cancer Date: 2020-07-31 Impact factor: 4.430
Authors: Melanie A Lindenberg; Valesca P Retèl; Joost H van den Berg; Marnix H Geukes Foppen; John B Haanen; Wim H van Harten Journal: J Immunother Date: 2018 Nov/Dec Impact factor: 4.456
Authors: Alexis Laurent; Nathalie Hirt-Burri; Corinne Scaletta; Murielle Michetti; Anthony S de Buys Roessingh; Wassim Raffoul; Lee Ann Applegate Journal: Front Bioeng Biotechnol Date: 2020-10-23